Beijing, Boston, MA, and San Diego, CA, March 17, 2025 — Biocytogen (“Biocytogen,” HKEX: 02315), a global biotech company advancing antibody-based drug discovery with innovative technologies, is pleased to announce the opening of its new office in San Diego, California, reinforcing its commitment to becoming the "global headstream of new drugs." This strategic expansion will enhance global partnerships in therapeutic antibody development and preclinical services, leveraging advanced technologies to accelerate the development of transformative therapeutics.
This new office will further Biocytogen’s mission to enhance global collaboration and drive innovation in drug discovery and development. By providing a comprehensive library of fully human antibodies, animal models and preclinical solutions, Biocytogen continues to strengthen its position as a strategic partner in advancing next-generation therapeutics. The San Diego location will integrate into the company’s global network, fostering relationships that support the accelerated translation of scientific breakthroughs into impactful solutions for global healthcare challenges.
To fulfill its vision as the "global headstream of new drugs," Biocytogen will continue focusing on the key areas in driving global collaboration and innovation:
- Strengthening Global Partnerships: Biocytogen deepens its partnerships with Top 20 global pharmaceutical companies and broadens its network of global collaborations. With fully human antibody discovery platforms and preclinical solutions, Biocytogen reinforces its role as a trusted partner in advancing transformative drug development.
- Enhancing Collaboration in Therapeutic Antibody Development: Through its proprietary RenMice® fully human antibody discovery platforms, Biocytogen empowers partners to develop breakthrough therapeutics, accelerating the translation of novel concepts into impactful treatments.
- Expanding Collaboration in Preclinical Solutions: Leveraging advanced humanized models and robust preclinical capabilities, Biocytogen aims to reduce uncertainties and optimize resources in drug development, enabling partners to bring transformative therapies to market more rapidly.
San Diego Office Address
9920 Pacific Heights Blvd Suite 150, San Diego, CA 92121
About Biocytogen
Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® (RenMab™/ RenLite®/ RenNano®/ RenTCR-mimic™ ) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR-mimic antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >400,000 fully human antibody sequences against approximately 1000 targets for worldwide collaboration. As of June 30, 2024, approximately 150 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and nearly 50 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit https://biocytogen.com/
Biocytogen Contacts
Antibody platform and assets: BD-Licensing@biocytogen.com
Preclinical models and services: info@biocytogen.com
Media: marketing@biocytogen.com
